论文部分内容阅读
目的:观察吉非替尼联合放疗治疗非小细胞肺癌脑转移的临床疗效及不良反应。方法:研究2006-06/2009-03非小细胞肺癌脑转移患者口服吉非替联合放疗的近期疗效和不良反应。采用直线加速器6MV-X线,全脑照射,2.0 Gy/f,DT 40 Gy/20f。同时口服吉非替尼250 mg/d,直至疾病进展或出现严重的不良反应。结果:9例患者中CR 1例,PR 4例,SD 2例,PD 2例,客观有效率56%,疾病控制率78%。主要不良反应为轻到中度的皮肤反应和腹泻,1例出现Ⅰ度骨髓抑制。结论:吉非替尼联合放疗治疗非小细胞肺癌脑转移疗效较好,不良反应轻微。
Objective: To observe the clinical efficacy and side effects of gefitinib in combination with radiotherapy in the treatment of brain metastases of non-small cell lung cancer. METHODS: To study the short-term efficacy and side effects of gefitinib combined with radiotherapy in patients with brain metastasis of non-small cell lung cancer from June 2006 to March 2009. Linear accelerator 6MV-X line was used, whole brain irradiation, 2.0 Gy / f, DT 40 Gy / 20f. Gefitinib orally 250 mg / d, until the disease progresses or serious adverse reactions. Results: Among the 9 patients, 1 was CR, 4 were PR, 2 were SD and 2 were PD. The objective response rate was 56% and the disease control rate was 78%. The main adverse reactions were mild to moderate skin reactions and diarrhea, and 1 case of grade I myelosuppression. Conclusion: Gefitinib combined with radiotherapy is effective in treatment of brain metastases of non-small cell lung cancer with mild adverse reactions.